Green Cross Corporation competitive analysis

Explore patent oppositions filed by Green Cross Corporation against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 17, 2026
Patent NumberTitleApplicantOpposition Date
Methods And Compositions For Cns Delivery Of Iduronate-2-SulfataseSHIRE HUMAN GENETIC THERAPIESMay 3, 2022
Cns Delivery Of Therapeutic AgentsSHIRE HUMAN GENETIC THERAPIESSep 9, 2021

Explore Green Cross Corporation's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 17, 2026
Patent NumberPublication DateTitleTotal Oppositions
May 10, 2023Composition And Formulation Comprising Recombinant Human Iduronate-2-Sulfatase And Preparation Method Thereof1

Latest PTAB cases involving Green Cross Corporation

Discover the latest PTAB cases involving Green Cross Corporation, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 17, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Green Cross Corporation

IPR2016-00258Nov 25, 2015GREEN CROSS CORPORATIONSHIRE HUMAN GENETIC THERAPIESFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Green Cross Corporation with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 17, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
GREEN CROSS CORPORATION211 -
JAMES POOLE204 - - -
SHIRE HUMAN GENETIC THERAPIES314 - 1
TAKEDA PHARMACEUTICAL128 - 1